Platform
Deciphera’s proprietary switch control platform has generated a diverse clinical pipeline of kinase inhibitor drug candidates including tumor-targeted therapies and immuno-targeted therapies.
Latest News
Jun
13
2018
Deciphera Pharmaceuticals, Inc. to Present at the JMP Securities 2018 Life Sciences Conference Read More »
Jun
11
2018
Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock Read More »
Jun
06
2018
Deciphera Pharmaceuticals Announces Pricing of Public Offering Read More »